PTC Therapeutics (PTCT)
NASDAQ:PTCT
Want to see PTCT full AI Analyst Report?
PTCT Stock Chart & Stats
$72.43
>-$0.01(-0.02%)
At close: 4:00 PM EST
$72.43
>-$0.01(-0.02%)
Day’s Range― - ―
52-Week Range$43.18 - $87.50
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.76M
Market Cap
$6.55B
Enterprise Value$6.08B
Total Cash (Recent Filing)$1.89B
Total Debt (Recent Filing)$395.09M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Jul 30, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.33
Shares Outstanding82,949,340
10 Day Avg. Volume2,431,135
30 Day Avg. Volume1,762,824
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-29.43
Price to Sales (P/S)3.49
P/FCF Ratio8.60
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue7.34
Enterprise Value/Gross Profit9.44
Enterprise Value/Ebitda-50.81
Forecast
1Y Price Target
$97.30Price Target Upside34.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.89
Revenue Forecast (FY)$1.17B
Bulls Say, Bears Say
Bulls Say
Sephience Commercial MomentumRobust Sephience launch demonstrates scalable commercial execution: consistent prescription starts (~140/mo), strong refill rates, broadening payer coverage and planned rollouts to ~30 countries. This establishes a durable product revenue engine that can sustain growth and fund pipeline investment over multiple years.
Strong Liquidity PositionNearly $1.9B in liquid resources provides a multi-quarter runway to support commercialization, clinical programs and strategic flexibility. That cash buffer reduces near-term financing pressure, enables planned vatiquinone and pipeline studies, and supports manufacturing and international launch investments.
Clinical Progress On Votoplam (Huntington's)Convincing 24‑month efficacy and favorable safety materially de‑risks the asset and validates the mechanism, supporting the Novartis‑led Phase 3 INVEST‑HD. This clinical strength can drive future milestone payments, partner support, and long‑term upside if Phase 3 confirms benefit in an unmet market.
Bears Say
Revenue And Profitability VolatilitySharp swings from 2025 profitability to TTM losses and a 52% revenue drop signal unstable topline and earnings. Such volatility complicates forecasting, weakens margin visibility, and increases reliance on new-product success or external financing to stabilize operations over the medium term.
Balance Sheet Leverage & Negative EquityNegative equity and material debt constrain financial flexibility and raise refinancing and covenant risks. Returns metrics are distorted, raising the likelihood of future dilution or costly financings to fund operations or repay converts, which can restrict strategic options and long‑term investment capacity.
Regulatory Delay For VatiquinoneNeeding an additional natural history‑controlled study shifts timelines and increases development cost for vatiquinone, delaying potential commercial revenue and HTA negotiations. The delay pressures resource allocation and defers value realization for a key pipeline asset, affecting multi‑year returns.
PTC Therapeutics News
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $43.17 and its highest was $87.50 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $6.55B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Jul 30, 2026 which is in 37 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.442.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is 0.32.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 82,949,340 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went up 14.266%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PTC Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$97.30 (34.34% Upside)
$97.30 (34.34% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 130.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.61%
12-Months-Change
Fundamentals
Return on Equity
99.84%
Trailing 12-Months
Asset Growth
8.05%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
PTCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution and materially positive topline results driven by Sephience (record product revenue, 36% QoQ Sephience growth, raised 2026 guidance), meaningful clinical progress in Huntington's (votoplam) and a defined regulatory plan for vatiquinone — all supported by a healthy balance sheet. Lowlights were largely operational or timing issues in mature products (one‑time Translarna order, Emflaza generic erosion), a modest quarter‑to‑quarter cash decline, and the need for an additional vatiquinone trial which delays NDA plans. Overall, the positives (robust launch, guidance raise, favorable HD data, pipeline momentum) substantially outweigh the manageable challenges.View all PTCT earnings summariesPTCT Stock 12 Month Forecast
Average Price Target
$97.30
▲(34.34% Upside)
Technical Analysis
Ownership Overview
1.44% Insiders
27.42% Mutual Funds
27.28% Other Institutional Investors
15.87% Public Companies and
Individual Investors